Understanding RAMS11 and its role in non-small cell lung cancer
Official title: Understanding the role of RAMS11 in non small cell lung cancer
Funded at Washington University · NIH-11333332 · Data updated 2026-11-12
This grant studies how a brainy RNA molecule called RAMS11 may drive aggressive non-small cell lung cancer and could lead to better biomarkers and targeted therapies for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | June 1, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $355,706 |
| NIH project number | 5R01CA293071-02 |
| Project ID | NIH-11333332 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with non-small cell lung cancer, particularly those whose tumors show NRF2 pathway mutations, could benefit from future biomarker and therapy developments.
✕Less likely to help
Patients whose tumors do not involve RAMS11 or NRF2-related biology may not benefit from this research.
What this research studies
Researchers will explore how the lncRNA RAMS11 promotes NSCLC, especially in tumors with NRF2 pathway mutations. They will use computational analyses and laboratory models to see how RAMS11 interacts with NRF2 and affects cancer-related gene programs. The goal is to identify markers and mechanisms that could guide future treatments for NSCLC patients.
Why it matters
Potential benefit: If successful, the work could yield new biomarkers and targets for therapies that help people with NSCLC live longer and with better quality of life.
How similar studies have gone: Previous studies have linked lncRNAs to cancer progression, with some RAMS11-like RNAs showing promise as biomarkers in lung cancer.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Maher, Christopher a — Washington University
- Study coordinator: Maher, Christopher a
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.